ITMI20002358A1 - Derivati di tieno ,2, 3-c|isochinolin-3-one come inibitori della poli(a dp-ribosio)polimerasi - Google Patents

Derivati di tieno ,2, 3-c|isochinolin-3-one come inibitori della poli(a dp-ribosio)polimerasi

Info

Publication number
ITMI20002358A1
ITMI20002358A1 IT002358A ITMI20002358A ITMI20002358A1 IT MI20002358 A1 ITMI20002358 A1 IT MI20002358A1 IT 002358 A IT002358 A IT 002358A IT MI20002358 A ITMI20002358 A IT MI20002358A IT MI20002358 A1 ITMI20002358 A1 IT MI20002358A1
Authority
IT
Italy
Prior art keywords
derivatives
ribose
polymerase
inhibitors
poly
Prior art date
Application number
IT002358A
Other languages
English (en)
Inventor
Flavio Moroni
Roberto Pellicciari
Original Assignee
Flavio Moroni
Roberto Pellicciari
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flavio Moroni, Roberto Pellicciari filed Critical Flavio Moroni
Priority to IT002358A priority Critical patent/ITMI20002358A1/it
Publication of ITMI20002358A0 publication Critical patent/ITMI20002358A0/it
Priority to EP01980788A priority patent/EP1332147A1/en
Priority to AU2002212575A priority patent/AU2002212575A1/en
Priority to ES04076527T priority patent/ES2332588T3/es
Priority to PCT/IB2001/002030 priority patent/WO2002036599A1/en
Priority to US10/415,601 priority patent/US6989388B2/en
Priority to AT04076527T priority patent/ATE444298T1/de
Priority to EP04076527A priority patent/EP1464646B1/en
Priority to JP2002539357A priority patent/JP4417622B2/ja
Priority to DE60140086T priority patent/DE60140086D1/de
Publication of ITMI20002358A1 publication Critical patent/ITMI20002358A1/it
Priority to US11/264,468 priority patent/US7825129B2/en
Priority to US12/938,163 priority patent/US20110237617A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IT002358A 2000-10-31 2000-10-31 Derivati di tieno ,2, 3-c|isochinolin-3-one come inibitori della poli(a dp-ribosio)polimerasi ITMI20002358A1 (it)

Priority Applications (12)

Application Number Priority Date Filing Date Title
IT002358A ITMI20002358A1 (it) 2000-10-31 2000-10-31 Derivati di tieno ,2, 3-c|isochinolin-3-one come inibitori della poli(a dp-ribosio)polimerasi
DE60140086T DE60140086D1 (de) 2000-10-31 2001-10-30 Thieno(2,3-c)isoquinolinen zur Verwendung als Parp-Inhibitoren
PCT/IB2001/002030 WO2002036599A1 (en) 2000-10-31 2001-10-30 Thieno[2,3-c]isoquinolines for use as inhibitors of parp
AU2002212575A AU2002212575A1 (en) 2000-10-31 2001-10-30 Thieno(2,3-c)isoquinolines for use as inhibitors of parp
ES04076527T ES2332588T3 (es) 2000-10-31 2001-10-30 Tieno(2,3-c)isoquinolinas para usar como inhibidores de parp.
EP01980788A EP1332147A1 (en) 2000-10-31 2001-10-30 Thieno[2,3-c isoquinolines for use as inhibitors of parp
US10/415,601 US6989388B2 (en) 2000-10-31 2001-10-30 Thieno[2,3-c]iosquinolines for use as inhibitors of PARP
AT04076527T ATE444298T1 (de) 2000-10-31 2001-10-30 Thieno(2,3-c)isoquinolinen zur verwendung als parp-inhibitoren
EP04076527A EP1464646B1 (en) 2000-10-31 2001-10-30 Thieno(2,3-C) Isoquinolines for use as inhibitors of Parp
JP2002539357A JP4417622B2 (ja) 2000-10-31 2001-10-30 Ｐａｒｐの阻害剤として用いるためのチエノ［２，３−ｃ］イソキノリン
US11/264,468 US7825129B2 (en) 2000-10-31 2005-11-01 Thieno[2,3-c] isoquinolines for use as inhibitors of PARP
US12/938,163 US20110237617A1 (en) 2000-10-31 2010-11-02 Thieno[2,3-c] isoquinolines for use as inhibitors of parp

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT002358A ITMI20002358A1 (it) 2000-10-31 2000-10-31 Derivati di tieno ,2, 3-c|isochinolin-3-one come inibitori della poli(a dp-ribosio)polimerasi

Publications (2)

Publication Number Publication Date
ITMI20002358A0 ITMI20002358A0 (it) 2000-10-31
ITMI20002358A1 true ITMI20002358A1 (it) 2002-05-01

Family

ID=11446071

Family Applications (1)

Application Number Title Priority Date Filing Date
IT002358A ITMI20002358A1 (it) 2000-10-31 2000-10-31 Derivati di tieno ,2, 3-c|isochinolin-3-one come inibitori della poli(a dp-ribosio)polimerasi

Country Status (9)

Country Link
US (3) US6989388B2 (it)
EP (2) EP1464646B1 (it)
JP (1) JP4417622B2 (it)
AT (1) ATE444298T1 (it)
AU (1) AU2002212575A1 (it)
DE (1) DE60140086D1 (it)
ES (1) ES2332588T3 (it)
IT (1) ITMI20002358A1 (it)
WO (1) WO2002036599A1 (it)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20002358A1 (it) * 2000-10-31 2002-05-01 Flavio Moroni Derivati di tieno ,2, 3-c|isochinolin-3-one come inibitori della poli(a dp-ribosio)polimerasi
US6956035B2 (en) * 2001-08-31 2005-10-18 Inotek Pharmaceuticals Corporation Isoquinoline derivatives and methods of use thereof
EA009875B1 (ru) 2003-11-20 2008-04-28 Янссен Фармацевтика Н.В. 6-алкенил и 6-фенилалкил замещенные 2-хинолиноны и 2-хиноксалиноны в качестве ингибиторов поли(адф-рибоза) полимеразы
JP4864718B2 (ja) * 2003-11-20 2012-02-01 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ポリ（ａｄｐ−リボース）ポリメラーゼ阻害剤としての６−アルケニルおよび６−フェニルアルキル置換２−キノリノンおよび２−キノキサリノン
EA011211B1 (ru) 2003-11-20 2009-02-27 Янссен Фармацевтика Н. В. 7-фенилалкилзамещённые 2-хинолиноны и 2-хиноксалиноны в качестве ингибиторов поли(адф-рибоза)полимеразы
MXPA06014541A (es) 2004-06-30 2007-03-23 Janssen Pharmaceutica Nv Derivados de quinazolindiona como inhibidores de la poli(adp-ribosa) polimerasa.
SG154433A1 (en) 2004-06-30 2009-08-28 Janssen Pharmaceutica Nv Phthalazine derivatives as parp inhibitors
MXPA06014933A (es) 2004-06-30 2007-02-28 Janssen Pharmaceutica Nv Derivados de 2-alquil quinazolinona sustituidos como inhibidores de poli(adp-ribosa) polimerasa-1.
CA2615374A1 (en) * 2005-07-18 2007-01-25 Ernest Kun Kun Treatment of cancer
US20100279327A1 (en) * 2006-06-12 2010-11-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
WO2008147418A1 (en) * 2006-06-12 2008-12-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
US20080262062A1 (en) * 2006-11-20 2008-10-23 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
GB0615809D0 (en) * 2006-08-09 2006-09-20 Istituto Di Ricerche D Biolog Therapeutic compounds
CA2662337A1 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Inhibition of fatty acid synthesis by parp inhibitors and methods of treatment thereof
JP2010502730A (ja) * 2006-09-05 2010-01-28 バイパー サイエンシズ，インコーポレイティド 癌の治療法
GB0701273D0 (en) * 2007-01-24 2007-02-28 Angeletti P Ist Richerche Bio New compounds
EP2126828A4 (en) * 2007-02-16 2012-01-25 Bodymedia Inc SYSTEMS AND METHODS FOR UNDERSTANDING AND APPLYING THE PHYSIOLOGICAL AND CONTEXTUAL LIFE PATTERNS OF ONE OR MORE INDIVIDUALS
US8299256B2 (en) 2007-03-08 2012-10-30 Janssen Pharmaceutica Nv Quinolinone derivatives as PARP and TANK inhibitors
WO2009047752A1 (en) * 2007-10-09 2009-04-16 Ramot At Tel-Aviv University Ltd. Breast cancer therapy
US9486449B2 (en) 2007-10-09 2016-11-08 Malka COHEN-ARMON Cancer therapy
US8404713B2 (en) 2007-10-26 2013-03-26 Janssen Pharmaceutica Nv Quinolinone derivatives as PARP inhibitors
CN103169973A (zh) * 2007-11-12 2013-06-26 彼帕科学公司 使用4-碘-3-硝基苯甲酰胺化合物与抗肿瘤剂组合治疗乳腺癌
KR20100102607A (ko) * 2007-11-12 2010-09-24 바이파 사이언스 인코포레이티드 Ｐａｒｐ 억제제를 단독으로 사용하거나 항종양제와 병용하여 자궁암 및 난소암을 치료하는 방법
CA2708157A1 (en) * 2007-12-07 2009-06-11 Bipar Sciences, Inc. Treatment of cancer with combinations of topoisomerase inhibitors and parp inhibitors
CA2713156A1 (en) * 2008-02-04 2009-08-13 Bipar Sciences, Inc. Methods of diagnosing and treating parp-mediated diseases
JP5464609B2 (ja) 2008-03-27 2014-04-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ チューブリン重合阻害剤としてのキナゾリノン誘導体
CA2716726C (en) 2008-03-27 2017-01-24 Janssen Pharmaceutica Nv Tetrahydrophenanthridinones and tetrahydrocyclopentaquinolinones as parp and tubulin polymerization inhibitors
SA109300394B1 (ar) * 2008-06-19 2013-01-22 ويث ثيازوليل- وأوكسازوليل- أيزوكوينولينونات وطرق لاستخدامها
CA2728466A1 (en) 2008-06-19 2009-12-23 Wyeth Llc Thienyl- and furanyl-isoquinolinones and methods for using them
WO2011058367A2 (en) 2009-11-13 2011-05-19 Astrazeneca Ab Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
CN103130723B (zh) 2011-11-30 2015-01-14 成都地奥制药集团有限公司 一种多聚(adp-核糖)聚合酶抑制剂
BR112014017833A2 (pt) 2012-01-20 2021-03-23 Dennis Brown Uso de hexitóis substituídos incluindo dianidrogalactitol e análogos para tratar doença neoplástica e células-tronco de câncer incluindo glioblastoma multiforme e meduloblastoma
EP2983674A4 (en) 2013-04-08 2017-05-10 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
CN105764501A (zh) 2013-07-26 2016-07-13 现代化制药公司 改善比生群治疗效益的组合物
KR102359214B1 (ko) 2014-04-04 2022-02-07 델 마 파마슈티컬스 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
JP6457696B2 (ja) 2015-07-23 2019-01-23 アンスティテュ・キュリＩｎｓｔｉｔｕｔ Ｃｕｒｉｅ 癌を処置するためのＤｂａｉｔ分子とＰＡＲＰインヒビターとの組合せの使用
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
US10874641B2 (en) 2016-07-28 2020-12-29 Mitobridge, Inc. Methods of treating acute kidney injury
AU2017355402A1 (en) 2016-11-02 2019-05-30 Health Research, Inc. Combination treatment with antibody-drug conjugates and PARP inhibitors
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
WO2018197461A1 (en) 2017-04-28 2018-11-01 Akribes Biomedical Gmbh A parp inhibitor in combination with a glucocorticoid and/or ascorbic acid and/or a protein growth factor for the treatment of impaired wound healing
KR20200130856A (ko) 2018-03-13 2020-11-20 옹쎄오 암 치료에서 획득한 내성에 대한 디베이트 분자
JP7798358B2 (ja) 2019-11-25 2026-01-14 ザ・リサーチ・ファウンデーション・フォア・ザ・ステイト・ユニバーシティー・オブ・ニューヨーク 癌の処置のためにタキサンと共にｆａｂｐ５阻害剤を使用する併用療法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
KR20260030809A (ko) 2023-06-21 2026-03-06 테트라곤 바이오사이언시스 엘티디 Hr 능숙형 암을 치료하는 방법에 사용하기 위한 데옥시시티딘 유도체 및 parp 억제제를 포함하는 조합

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1054655B (it) * 1975-08-27 1981-11-30 Lepetit Spa Derivati condensati del l isochinolina
US4263304A (en) * 1978-06-05 1981-04-21 Sumitomo Chemical Company, Limited 7 H-indolo[2,3-c]isoquinolines
US6358975B1 (en) * 1997-08-15 2002-03-19 Johns Hopkins University Method of using selective parp inhibitors to prevent or treat neurotoxicity
US6514983B1 (en) * 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
CA2332239A1 (en) * 1998-05-15 1999-11-25 Guilford Pharmaceuticals Inc. Fused tricyclic compounds which inhibit parp activity
ITMI20002358A1 (it) * 2000-10-31 2002-05-01 Flavio Moroni Derivati di tieno ,2, 3-c|isochinolin-3-one come inibitori della poli(a dp-ribosio)polimerasi

Also Published As

Publication number Publication date
WO2002036599A1 (en) 2002-05-10
EP1332147A1 (en) 2003-08-06
US20040082789A1 (en) 2004-04-29
EP1464646B1 (en) 2009-09-30
JP4417622B2 (ja) 2010-02-17
DE60140086D1 (de) 2009-11-12
EP1464646A1 (en) 2004-10-06
US7825129B2 (en) 2010-11-02
US6989388B2 (en) 2006-01-24
US20060094746A1 (en) 2006-05-04
US20110237617A1 (en) 2011-09-29
ATE444298T1 (de) 2009-10-15
ES2332588T3 (es) 2010-02-09
AU2002212575A1 (en) 2002-05-15
ITMI20002358A0 (it) 2000-10-31
JP2004520273A (ja) 2004-07-08

Similar Documents

Publication Publication Date Title
ITMI20002358A1 (it) Derivati di tieno ,2, 3-c|isochinolin-3-one come inibitori della poli(a dp-ribosio)polimerasi
TR200102005T2 (tr) Poli(adp-ribaz) polimerazların trisiklik inhibitörleri.
EA200200306A1 (ru) Трициклические ингибиторы поли(адф-рибозо)полимераз
WO2001064214A3 (en) Compositions and methods for the treatment of inflammatory diseases using topoisomerase inhibitors
NZ516562A (en) Pyrimidine-2,4,6-trione metalloproteinase inhibitors
NO20054988D0 (no) Preparater og metoder for behandling av cancer
BR0011130A (pt) Inibidores de metaloproteases
IS2520B (is) Nikótínamíð afleiður nytsamlegar sem P38 hindrar
CY1110527T1 (el) Διαρυλ ενωσεις ως αναστολεις πρωτεασης σερινης
MY135766A (en) Quinolinones and naphthyridinones for treating inflammatory diseases
PT1268480E (pt) Derivados de 8-quinolinil-xantina e 8-isoquinolinil-xantina como inibidores da pde 5
CY1107531T1 (el) Χρηση αναστολεων πρωτεασομης για την αγωγη των διαταραχων ξηρου οφθαλμου
NO20032636D0 (no) 3-indolinderivater som er nyttige i behandlingen av psykiatriske og nevrologiske forstyrrelser
IS6594A (is) 2-asýl indól afleiður og notkun þeirra sem miðla gegn æxlum
DE60121345D1 (de) Alkylierte imidazopyridinderivate
TR200401316T4 (tr) Proliferatif hastalıkları tedavi etmek için yöntemler ve bileşikler
AR034343A1 (es) Combinaciones farmaceuticas
NO20024076D0 (no) Sammensetning omfattende camptotecin og et pyrimidinderivat for behandling av cancer
ATE316954T1 (de) N-biphenylmethylaminocycloalkancarboxamid- derivative
DE60115466D1 (de) Wirkstoffvorläufer von imidazopyridin-derivaten
NO20041214L (no) Substituerte benzimidazolforbindelser og deres anvendelse for behandling av cancer
BR0213994A (pt) Derivados heterocìclicos de glicinamida e seus usos médicos
AR024380A1 (es) Tienopirimidinas
ATE325115T1 (de) Pyrimidinderivate als selektive cox-2-inhibitoren
TR200302134T4 (tr) 2-metil-tiazolidin-2,4-dikarboksilik asit ve/veya bunun fizyolojik olarak uygun tuzlarının anti-kanser ajanları olarak kullanımı.